# Biocon Ltd (BIOCON)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹430.85
Day Change: -0.43%
52W High: ₹434.6
52W Low: ₹327.6
Market Cap: ₹68,635 Cr

## Valuation
P/E: 149.24
P/B: 1.98
EPS: ₹2.84
Book Value: ₹213.54
Dividend Yield: 0.12%

## Returns
1Y Return: 5.96%

## Profitability
ROE: 1.15%
ROCE: 4.69%
Debt/Equity: 0.42
Revenue Growth: 2.3%
Profit Growth: -72.5%
EBITDA Margin: 20.41%
Operating Margin: 11.22%

## About
Biocon Ltd is a Biotechnology company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Biotechnology
Sub Industry: Unknown

## Business Model
Overview: Biocon Ltd makes money through Technology services, Digital transformation projects, Maintenance and managed services in Biotechnology. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Technology services
- Digital transformation projects
- Maintenance and managed services
Operating Model:
- Wins client contracts, deploys skilled delivery teams, and earns project or recurring service revenue.
- Utilisation, billing rates, attrition, and currency movements are key operating levers.
Recent Context:
- Concall Transcript: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Announcement: Company Statement
- BSE Filing: Company Statement

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:00.503Z
Price History Updated: 2026-05-17T21:24:52.342Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:24:52.342Z
Quant Updated: 2026-05-17T21:24:52.342Z
Sentiment Updated: 2026-05-17T21:24:52.342Z
Financials Status: current
Financials Updated: 2026-05-18T04:30:13.779Z
Financials Last Attempt: 2026-05-18T04:30:13.779Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016)
Revenue: ₹3090 Cr
Operating Profit: ₹696 Cr (OPM 23%)
Net Profit: ₹528 Cr
Tax: ₹624 Cr

## Annual P&L History
Mar 2016: Rev ₹3090Cr | PAT ₹528Cr | OPM 23%
Mar 2017: Rev ₹3347Cr | PAT ₹609Cr | OPM 12%
Mar 2018: Rev ₹3891Cr | PAT ₹688Cr | OPM 25%

## Balance Sheet (Mar 2016)
Total Assets: ₹6375 Cr
Total Liabilities: ₹6375 Cr
Borrowings: ₹1117 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Kiran  Mazumdar-Shaw B.Sc (Hons), B.Sc., Founder & Executive Chairperson
- Shreehas Pradeep Tambe MTech, CEO, MD & Additional Director
- Kedar Narayan Upadhye CS, MBA, Chief Financial Officer
- Mandar S. Ghatnekar, Chief Technology Officer
- Saurabh  Paliwal, Head of Investor Relations

---
Source: rupiya.io/stocks/biocon
Disclaimer: For research and education only. Not investment advice.